KPV
Also known as: lysine-proline-valine · alpha-MSH(11-13)
The C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory activity apparently independent of melanocortin receptor binding.
Development status: Preclinical — laboratory and animal studies only
Identifiers and molecular characteristics
- CAS number
- Not verified
- Molecular formula
- Not verified
- Molecular mass
- Not verified
- Amino-acid sequence
- Not verified
- PubChem CID
- Not verified
Identifiers are published only with a source and a check date. Fields marked “not verified” have not yet been confirmed against a primary source — we show the gap rather than an unchecked figure. Always confirm against the certificate of analysis for the specific lot you hold.
Biological targets
- Reported intracellular NF-κB pathway effects
Mechanism of action
Reported to act intracellularly on inflammatory signalling rather than through melanocortin receptors, which distinguishes it from the parent hormone.
Research evidence and its limits
Cell and animal models of inflammation. No human trials known to this entry.
Safety considerations
No regulatory authority has assessed this compound as safe or effective for any human indication. The published record is predominantly laboratory and animal work, which does not establish human safety. Supplied and discussed here strictly as a laboratory research material. Not a medicine, not for human or veterinary administration, and nothing on this page should be read as a dosing, treatment or safety recommendation.
Analytical identification and quality testing
Identity by high-resolution mass spectrometry against the expected mass, purity by RP-HPLC with UV detection. Tandem MS sequencing or peptide mapping gives stronger identity evidence than mass alone.
Regulatory status
Not an approved medicine.
References
Related compounds
Entry last reviewed 2026-10-11. Regulatory status and scientific understanding change; verify against primary sources before relying on anything here.